Next, we analyzed the CAR safety of targeting B lineage-related target antigens (CD19, MS4A1, CD22, TNFRSF17, CD38, SLAMF7, and TNFRSF8), AML-related target antigens (CD33, CD123, and CLEC12A), and solid tumor-related target antigens (GPC3, B4GALNT1, and ERBB2). This evidence concerns the gene CLEC12A and acute myeloid leukemia.